Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
10.1245/s10434-008-9970-6
Annals of Surgical Oncology 15:2739-2748 (2008)
© 2008 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lahat, G.
Right arrow Articles by Pollock, R. E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Lahat, G.
Right arrow Articles by Pollock, R. E.

Original Article

New Perspectives for Staging and Prognosis in Soft Tissue Sarcoma

G. Lahat, MD1,2, D. Tuvin, MD1,2, C. Wei, PhD3, D. A. Anaya, MD1, B. N. Bekele, PhD4, A. J. Lazar, MD, PhD2,5, P. W. Pisters, MD1, D. Lev, MD2,6 and R. E. Pollock, MD, PhD1,2

1 Department of Surgical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe St., Unit 1104, Houston, TX 77030, USA
2 Sarcoma Research Center, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
3 Division of Quantitative Sciences, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
4 Department of Biostatistics, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
5 Department of Pathology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
6 Department of Cancer Biology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

Correspondence: Address correspondence and reprint requests to: G. Lahat, MD; E-mail: glahat{at}mdanderson.org

Background: Data suggest that the current American Joint Committee on Cancer (AJCC) soft tissue sarcoma (STS) staging criteria merit further evaluation. We sought to identify and validate factors as enhanced descriptors of STS clinical behavior.

Methods: Prospectively accrued data were analyzed for 1,091 AJCC stage I to III primary STS patients who had complete macroscopic resection at our institution from 1996 to 2007. Study factors were examined by univariable and multivariable analyses to identify independent prognostic factors for disease related mortality and overall survival (OS).

Results: In contrast to the current AJCC STS staging system, which stratifies size into T1 (≤5 cm) and T2 (>5 cm) groups, we demonstrated three distinct cohorts (P <0.0001): T1 (≤5 cm; 5-year OS 85%), T2 (5 to 15 cm; OS 68%), and T3 (>15 cm; OS 52%). A two-category system of histologic grade was demonstrably as informative as the current four histologic grade AJCC system. A multivariable Cox proportional hazard model identified tumor size (5 to 15 cm vs. ≤5 cm, P = 0.03; or>15 cm vs. ≤5 cm; P <0.0001), nonextremity primary site (P = 0.0016), disease of high histologic grade (P = 0.001), specific histology (P = 0.001), and margin positivity (P <0.0001) as statistically significant adverse independent prognostic factors. Recurrence during follow-up was the most significant risk factor for STS-specific mortality (P <0.0001).

Conclusion: Tumor size and grade in the AJCC STS staging system need revision; moreover, primary site, histologic subtype, margin status, and recurrence offer additional relevant prognostic insight. Incorporation of these factors may enhance the AJCC staging system, thereby further facilitating individualized therapeutic strategies for STS patients.

Key Words: Soft tissue sarcoma • Staging • Prognostic factors • Recurrence • Survival






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the Society of Surgical Oncology.